Crossing the blood-brain barrier: Integrating scientific innovation with socio-ethical reflection in predictive medicine

Psychiatric Times

Volumn 24, Issue 10, 2007, Pages 28-34

  Ozdemir, Vural ^a,b   Godard, Béatrice ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Pacific Rim Association for Clinical Pharmacogenetics

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34948861196     PISSN: 08932905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Eichelbaum M, Fromm MF, Schwab M. Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther Drug Monit. 2004;26:180-185.
2. Doran A, Obach RS, Smith BJ, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos. 2005;33:165-174.
3. Lee G, Bendayan R. Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm Res. 2004;21:1313-1330.
4. Kirby BJ, Unadkat JD. Grapefruit juice, a glass full of drug interactions? Clin Pharmacol Ther. 2007;81:631-633.
5. Glaeser H, Bailey DG, Dresser GK, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther. 2007;81:362-370.
6. Preskom SH. Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future. J Psychopharmacol. 2006;20:85-94.
7. Ozdemir V, Godard B. Evidence based management of nutrigenomics expectations and ELSIs. Pharmacogenomics. In press.
8. Godard B, Marshall J, Laberge C, Knoppers BM. Strategies for consulting with the community: the cases of four large-scale genetic databases. Sci Eng Ethics. 2004;10:457-477.
9. Rose N. The Politics of Life Itself: Biomedicine, Power, and Subjectivity in the Twenty-First Century. Princeton, NJ: Princeton University Press; 2006.
10. Williams-Jones B, Ozdemir V. Pharmacogenomic promises: reflections on semantics, genohype and global justice. In: Einsiedel E, ed. Emerging Technologies: From Hindsight to Foresight. Calgary, AB, Canada: University of Calgary Press. In press.
11. Rose N. Genomics. In: Kuper A, Kuper J, eds. The Social Science Encyclopedia. 3rd ed. London, UK: Routledge; 2004.
12. Graham J, Ritchie K. Mild cognitive impairment: ethical considerations for nosological flexibility in human kinds. Philos Psychol Psychiatry. 2006;13:31-43.
13. Sadeque AJ, Wandel C, He H, et al. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther. 2000;68:231-237.
14. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71:163-169.
15. Wang JS, Ruan Y, Taylor RM, et al. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol. 2004;7:415-419.
16. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol. 2007;47:566-578.
17. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci. 2006;78:2131-2145.
18. Bertilsson L, Aberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit. 1985;7:478-480.
19. Kirchheiner J, Fuhr U, Brockmoller J, Pharmacogenetics-based therapeutic recommendations - ready for clinical practice? Nat Rev Drug Discov. 2005;4:639-647.
20. Achira M, Suzuki H, Ito K, Sugiyama Y. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS PharmSci. 1999;1:E18.
21. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999;16:408-414.
22. Wandel C, Kim RB, Kajiji S, et al. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 1999;59:3944-3948.
23. Muhr C. Positron emission tomography in acromegaly and other pituitary adenoma patients. Neuroendocrinology. 2006;83:205-210.
24. Moresco RM, Cavallaro R, Messa C, et al. Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol. 2004;18:355-365.
25. US Department of Health and Human Services. Food and Drug Administration. Innovation or Stagnation. Challenge and Opportunity on the Critical Path to New Medical Products. Rockville, MD: US Food and Drug Administration; March 2004.
26. Ozdemir V, Williams-Jones B, Cooper DM, et al. Mapping translational research in personalized therapeutics: from molecular markers to health policy. Pharmacogenomics. 2007;8:177-185.
27. Littman BH, Di Mario L, Plebani M, Marincola FM. What's next in translational medicine? Clin Sci (Lond). 2007;112:217-227.
28. Hopkins MM, Ibarreta D, Gaisser S, et al. Putting pharmacogenetics into practice. Nat Biotechnol. 2006;24:403-410.
29. Atkinson-Grosjean J. Public Science, Private Interests: Culture and Commerce in Canada's Networks of Centres of Excellence. Toronto, ON, Canada: University of Toronto Press; 2006.
30. Williams-Jones B. Knowledge commons or economic engine - what's a university for? J Med Ethics. 2005;31:249-250.
31. Graham J. Smart regulation: will the government's strategy work? CMAJ. 2005;173:1469-1470.
32. Hedgecoe A. The Politics of Personalised Medicine: Pharmacogenetics in the Clinic. Cambridge, UK: Cambridge University Press; 2004.
33. Etzkowitz H, Webster A, Gebhardt C, Cantisano-Terra BR. The future of the university and the university of the future: evolution of ivory tower to entrepreneurial paradigm. Res Policy. 2000;29:313-330.
34. Cantor MD, Barach P, Derse A, et al. Disclosing adverse events to patients. Jt Comm J Qual Patient Saf. 2005;31:5-12.
35. Parker LS. Ethical issues in bipolar disorders pedigree research: privacy concerns, informed consent, and grounds for waiver. Bipolar Disord. 2002;4:1-16.
36. Hedgecoe A. Education, ethics and knowledge deficits in clinical pharmacogenetics. Pharmacogenomics. 2007;8:267-270.
37. de Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics. 2006;47:75-85.
38. Kirchheiner J, Fuhr U, Brockmoller J. Pharmacogenetics-based therapeutic recommendations - ready for clinical practice? Nat Rev Drug Discov. 2005;4:639-647.